C642D475-8BD8-44CA-B07E-A6822B2224C4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.307490144546648
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.466
- INTERFERON_ALPHA_RESPONSE+0.443
- NOTCH_SIGNALING+0.435
- PROTEIN_SECRETION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.408
- INTERFERON_GAMMA_RESPONSE+0.356
- MTORC1_SIGNALING+0.349
- MYC_TARGETS_V2+0.343
- OXIDATIVE_PHOSPHORYLATION+0.342
- TGF_BETA_SIGNALING+0.319
Top 10 suppressed
- KRAS_SIGNALING_DN-0.363
- SPERMATOGENESIS-0.322
- PANCREAS_BETA_CELLS-0.162
- APICAL_SURFACE-0.156
- BILE_ACID_METABOLISM-0.083
- ESTROGEN_RESPONSE_LATE-0.079
- MYOGENESIS-0.059
- UV_RESPONSE_DN-0.052
- APICAL_JUNCTION-0.027
- ESTROGEN_RESPONSE_EARLY+0.001
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.933 |
| 2 | 9041BE5E-3BC7-4495-9461-8FFA2CAEB524 | — | — | 0.922 |
| 3 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.916 |
| 4 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.911 |
| 5 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.908 |
| 6 | 7AA08B08-B1DD-47AB-A0F2-850F6DE95093 | — | — | 0.899 |
| 7 | B66ECF23-8CB2-4C95-8E3D-AA63A494F4A0 | — | — | 0.899 |
| 8 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.897 |
| 9 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.897 |
| 10 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.466 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.443 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.435 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.408 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.356 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.349 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.343 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.342 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.319 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.306 | Idelalisib | — uncovered |
| APOPTOSIS | 0.295 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.274 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.258 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.252 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.238 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.236 | Remibrutinib | — uncovered |